Related Experiment Videos
Maximum lipid reduction by partial ileal bypass: a test of the lipid-atherosclerosis hypothesis
Insights
Partial ileal bypass surgery effectively lowers plasma cholesterol, a key factor in atherosclerosis and coronary heart disease. This surgical approach offers a promising, reliable method for managing hyperlipidemia and reducing cardiovascular disease risk.
Area of Science:
- Cardiovascular Medicine
- Surgical Innovation
- Lipid Metabolism
Background:
- Atherosclerosis is the primary cause of coronary heart disease, with plasma cholesterol concentration as a major risk factor.
- Conclusive evidence demonstrating that cholesterol reduction mitigates atherosclerosis and cardiovascular disease incidence/severity is still needed.
- Previous trials investigating lipid-lowering interventions have yielded controversial methods and inconclusive results.
Purpose of the Study:
- To review existing data on lipid-lowering trials and their outcomes.
- To evaluate surgical interventions as a definitive test of the lipid hypothesis.
- To present partial ileal bypass as an ideal modality for lipid reduction.
Main Methods:
- Review of first and second-generation lipid-lowering trials.
- Evaluation of partial ileal bypass surgery based on six ideal trial characteristics.
- Outline of the National Heart and Lung Institute Program on Surgical Control of the Hyperlipidemias trial design.
Main Results:
- Partial ileal bypass surgery demonstrates maximum effectiveness, achieving a 50% cholesterol reduction.
- The procedure has a known mechanism of action, no response escape/rebound, and obligatory effect.
- Partial ileal bypass exhibits minimal side effects and relative safety.
Conclusions:
- Partial ileal bypass surgery is a highly effective and reliable lipid-lowering intervention.
- This surgical modality provides a definitive approach to testing the lipid hypothesis.
- The outlined National Heart and Lung Institute trial will further investigate diet and partial ileal bypass for hyperlipidemia management.
Abstract:
Atherosclerosis is the process responsible for our national epidemic of coronary heart disease. A primary and proven atherosclerotic risk factor is the plasma cholesterol concentration. Yet, proof that a reduction in plasma cholesterol level results in a reduction in the incidence or severity of atherosclerosis and atherosclerotic cardiovascular disease still requires conclusive documentation. The controversial methods of operation and inconclusive results of concluded first and second generation trials are reviewed. These data clearly demonstrate that a definitive test of the lipid hypothesis has not been reported. Evidence is presented to show that the partial ileal bypass operation most nearly fulfills the six features of an "ideal" lipid lowering trial modality: maximum effectiveness (50% cholesterol reduction); known mechanism of action; no response "escape" or "rebound"; obligatory effect without patient cooperation; minimal side effects; and relative safety. The basic design and protocol of the National Heart and Lung Institute Program on Surgical Control of the Hyperlipidemias, a secondary intervention trial using a combination of diet therapy and partial ileal bypass surgery, are outlined.